IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMM - IMMUTEP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.295

22 Jul
2024

0.000

OPEN

$0.30

0.000

HIGH

$0.31

2,454,789

LOW

$0.29

TARGET
$0.75 154.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMM: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 4.4 - 3.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-4.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx11.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-35.4 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-34.61 %
Return on Invested Capital xxxxxxxxxxxxxxx-34.22 %
Return on Assets xxxxxxxxxxxxxxx-31.97 %
Return on Equity xxxxxxxxxxxxxxx-34.61 %
Return on Total Capital xxxxxxxxxxxxxxx-38.49 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-35.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx123 M
Price To Book Value xxxxxxxxxxxxxxx2.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx43 M
Research & Development xxxxxxxxxxxxxxx29 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

16/07/2024

1

Speculative Buy

$0.75

154.24%

Immutep has provided a data update from Cohort B of the Phase 2 trial, which provides further encouragement that Efti and Keytruda could provide a chemo-free option with improved efficacy, according to Bell Potter.

The trial is aiming to benefit patients with first line head and neck squamous cell carcinoma (HNSCC), explains the broker. The 35.5% objective response rate (ORR) for Efti and Keytruda is similar to the ORR achieved historically with the current chemo-based approach.

The Speculative Buy rating and 75c target are maintained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -3.20 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.70 cents.
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

21/05/2024

1

Buy

$1.00

238.98%

Immutep presented data from the AIPAC-003 trial for its lead candidate, Eftilagimod Alpha, at the European Society for Medical Oncology (ESMO), notes Canaccord Genuity.

The trial, targeting HR-positive/HER2-negative/low metastatic breast cancer, showed continued safety with no new adverse events, which is crucial, according to the analyst, given recent competitor safety issues.

Overall response rate was 50%, with one complete response and a 100% disease control rate.

The broker is looking to results from a randomised head and neck cancer trial plus details on a Phase III lung cancer trial. Canaccord Genuity maintains a Buy rating on Immutep, with a target price of $1.00.
Access Stockbroker Research History >

IMM STOCK CHART

FNArena News on IMM

1
Rudi’s View: Rate Cuts, Growth & Small Caps

Jul 18 2024 - Rudi's View
2
Rudi’s View: Gold, Healthcare, Staples & Copper

Jul 11 2024 - Rudi's View
3
Rudi’s View: Met Coal, Banks, GenAi & Buying-The-Dip

Jul 04 2024 - Rudi's View
4
Australian Broker Call *Extra* Edition – Jul 03, 2024

Jul 03 2024 - Daily Market Reports
5
Rudi’s View: Copper, Lithium, Retailers & TechnologyOne

Jun 27 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

10:30 AM - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps